Viatar CTC Solutions Reports Third Quarter 2015 Highlights

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Viatar CTC Solutions Reports Third Quarter 2015 Highlights and Financial Results

LOWELL, MA--(Marketwired - Nov 13, 2015) - Viatar CTC Solutions, Inc. (OTCQB: VRTT), a medical technology company focused on the treatment of patients with metastatic cancer, today announced highlights and financial results for the third quarter ended September 30, 2015.

  • Generated $37,940 of revenue over the past four quarters from sales of Viatar's proprietary filters to a strategic collaborator, for use in that company's liquid biopsy device for molecular analysis.
  • Received the prestigious Cavendish Global Health Innovation Award at the Cavendish Global Health Impact Forum co-hosted by Cleveland Clinic in October 2015.

For the third quarter of 2015, Viatar reported sales of $13,985 compared to no sales in the comparable quarter of 2014. For the first nine months of 2015, Viatar reported sales of $37,940 compared to $9,000 for the first nine months of 2014. Earlier this year, those sales were connected to evaluation testing of the Company's filters, but in the third quarter the Company's filters were integrated into a customer's product line for use by medical researchers at prominent cancer institutions.

Research & development expenses during the third quarter of 2015 were $677,878 compared to $552,321 in the third quarter of 2014. General and administrative expenses during the third quarter of 2015 were $250,648 compared to $136,031 in the third quarter of 2014. Expense increases reflect the ongoing development of the Company's two products based on its proprietary CTC removal technology as well as the required costs associated with being a public company.

Viatar reported a net loss of $934,784 for the third quarter of 2015 compared to a net loss of $706,015 for the comparable period in 2014. These losses include $160,266 and $346,379, respectively, of non-cash expenses for stock-based compensation.

For the nine months ended September 30, 2015 Viatar reported a net loss of $2,880,124, which included $857,515 of non-cash expenses for stock-based compensation.

At September 30, 2015, Viatar had cash assets of $107,432. In October 2015, the Company received $1.3 million in exchange for 4% convertible promissory notes due July 2018.

"Viatar's profile has begun to rise with our selection for the respected Cavendish Global Health Innovation Award and through our participation in investment conferences and ongoing investor meetings," said Ilan Reich, Chairman and CEO of Viatar CTC Solutions. "We also continue to meet our timetable for achieving CE Mark regulatory approval for Europe and Canada in late-2016, after which we can begin commercialization. A parallel effort is also underway to obtain FDA approval, but that will take several years due to the vastly different regulatory requirements."

Additional information can be found in the Company's Form 10Q for the period ended September 30, 2015.

About Viatar CTC Solutions

Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The company's lead product, the Viatar™ Therapeutic Oncopheresis System, removes circulating tumor cells from whole blood using label-free cross-flow filtration. Pending regulatory approval targeted for 2016, it will be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate and gastric cancers.

This proprietary technology also powers the company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives.   

   
   
Viatar CTC Solutions Inc. and Subsidiary  
   
Condensed Consolidated Statements of Operations  
(Unaudited)  
                         
                         
    For the Nine Months Ended September 30,     For the Three Months Ended September 30,  
    2015     2014     2015     2014  
                                 
                                 
REVENUE                                
  Sales   $ 37,940     $ 9,000     $ 13,985     $ -  
                                 
COST OF REVENUE                                
  Cost of sales     7,660       -       3,830       -  
                                 
GROSS MARGIN     30,280       9,000       10,155       -  
                                 
EXPENSES                                
  Research and development     1,889,156       982,450       677,878       552,321  
  General and administrative     948,116       806,176       250,648       136,031  
                                 
TOTAL EXPENSES     2,837,272       1,788,626       928,526       688,352  
                                 
LOSS FROM OPERATIONS     (2,806,992 )     (1,779,626 )     (918,371 )     (688,352 )
                                 
OTHER INCOME (EXPENSE)                                
  Change in value of derivative liability     -       1,800       -       -  
  Interest expense     (73,132 )     (17,663 )     (16,413 )     (17,663 )
                                 
TOTAL OTHER INCOME (EXPENSE)     (73,132 )     (15,863 )     (16,413 )     (17,663 )
                                 
LOSS BEFORE INCOME TAX (EXPENSE) BENEFIT     (2,880,124 )     (1,795,489 )     (934,784 )     (706,015 )
                                 
  Income tax (expense) benefit     -       -       -       -  
                                 
NET LOSS     (2,880,124 )     (1,795,489 )     (934,784 )     (706,015 )
                                 
  Net loss attributable to noncontrolling interest in consolidated subsidiary     (393 )     (280 )     (120 )     (194 )
                                 
NET LOSS ATTRIBUTABLE TO STOCKHOLDERS   $ (2,879,731 )   $ (1,795,209 )   $ (934,664 )   $ (705,821 )
                                 
LOSS PER COMMON SHARE - BASIC AND DILUTED:                                
  Net Loss Attributable to Common Stockholders   $ (0.16 )   $ (0.12 )   $ (0.05 )   $ (0.04 )
  Weighted Average Shares     17,604,366       15,556,312       17,981,054       15,918,177  
                                 
                                 
   
   
Viatar CTC Solutions Inc. and Subsidiary  
   
Condensed Consolidated Balance Sheets  
             
             
    September 30, 2015     December 31, 2014  
    (Unaudited)        
                 
ASSETS                
                 
CURRENT ASSETS                
  Cash   $ 107,432     $ 31,351  
                 
      TOTAL ASSETS   $ 107,432     $ 31,351  
                 
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT                
                 
CURRENT LIABILITIES                
  Accounts payable and accrued expenses   $ 190,595     $ 290,210  
  Accrued income tax liability     762,637       732,550  
  Demand note payable     -       50,000  
  Convertible note payable     -       93,495  
                 
    Total current liabilities     953,232       1,166,255  
                 
  Convertible note payable, net     400,000       -  
                 
      TOTAL LIABILITIES     1,353,232       1,166,255  
                 
  Commitments and contingencies                
                 
STOCKHOLDERS' DEFICIT                
                 
  Series A preferred stock, $.001 par value, 20,000,000 shares authorized, 4,000,000 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively     4,000       4,000  
  Common stock, $.001 par value, 100,000,000 shares authorized, 18,107,176 and 16,814,426 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively     18,108       16,815  
  Common stock subscription and interest receivable     -       (605,475 )
  Additional paid-in capital     19,773,834       17,611,374  
  Accumulated deficit     (21,031,520 )     (18,151,789 )
      Total stockholders' deficit     (1,235,578 )     (1,125,075 )
                 
  Noncontrolling interest     (10,222 )     (9,829 )
                 
      TOTAL STOCKHOLDERS' DEFICIT     (1,245,800 )     (1,134,904 )
                 
      TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT   $ 107,432     $ 31,351  
                     
                     

For More Information: For Viatar CTC Solutions: Ilan Reich Chairman & CEO ilan.reich@viatarctcsolutions.com Investor Contacts: Stephanie Prince PCG Advisory Group 646.762.4518 Sprince@pcgadvisory.com Dave Gentry RedChip Companies 407-644-4256, ext. 104 dave@redchip.com Media Contact: Sean Leous PCG Advisory Group 646.863.8998 Sleous@pcgadvisory.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 23

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Protein Now! Gains Clinician Attention, With Caveats

Updated Category News Views 91

A Small Bottle Has Drawn a Crowd Protein powder tubs have been cluttering kitchens for years; a 3.38-fluid-ounce shot is a cleaner answer to the same daily hassle. NutraBio Labs says more than 800 physicians, nurse practitioners, and physician associates had added PROTEIN NOW! to their individual FrontrowMD patient pages as of November 2026. That earned the product a...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 14

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 113

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading

Top 5 Most Recently Viewed Articles

ICG Enterprise Trust plc Announces Share Repurchase Details

Updated Category News Views 159

ICG Enterprise Trust plc Share Buyback Announcement ICG Enterprise Trust plc (the “Company”) The Company has announced a recent development regarding its share buyback initiative. On a significant date, it repurchased 15,000 of its own shares aimed to be held as treasury shares, with each share valued at an average price of 1450 pence. Details of the Transaction...

Continue Reading
Converge Technology Solutions Shares Third Quarter 2024 Insights

Updated Category News Views 217

Converge Technology Solutions Announces Preliminary Q3 Results Converge Technology Solutions Corp. (CTS) has released its preliminary unaudited financial results for the third quarter of 2024. The company is committed to delivering insightful updates to its stakeholders as part of its transparency approach. The company stated that all figures are presented in Canadian...

Continue Reading
Discovery Silver Corp. Unveils 2023 ESG Report

Updated Category News Views 104

Discovery Silver Corp. Releases 2023 ESG Report Key Highlights: Earned Quality Environmental Certification from the Mexican Government Recognized as a Socially Responsible Enterprise by the Mexican Center for Philanthropy Achieved Great Place to Work Certification Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) is excited to announce the publication of its 2023...

Continue Reading
Final Call for Subscription in IDEX Biometrics Offering Today

Updated Category News Views 152

Important Subscription Period Details for IDEX Biometrics Today marks a significant turning point for IDEX Biometrics ASA as the subscription period for their subsequent offering of shares closes. The company previously announced that they aim to issue up to 600 million new shares at a remarkable subscription price of NOK 0.01 per share. This offering, essential for...

Continue Reading
Dundee Corporation Strengthens Position in Greenheart Gold Inc.

Updated Category News Views 33

Overview of Recent Acquisition Dundee Corporation (TSX: DC.A) has announced that its wholly-owned subsidiary, Dundee Resources Limited, recently acquired 2,000,000 common shares of Greenheart Gold Inc. (TSXV: GHRT) at a price of C$0.50 per share, totaling an investment of C$1,000,000. This acquisition is part of the Issuer's bought deal private placement and signifies...

Continue Reading